

Hansa Medical

- PRESS RELEASE -
December 8, 2015

Swedish and international investors acquire 2 million shares in Hansa Medical AB from Farstorps Gård AB

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SWITZERLAND, SOUTH AFRICA, SINGAPORE, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Stockholm, December 8, 2015 – Hansa Medical AB (publ) ("Hansa Medical") has been informed that Farstorps Gård AB has sold 2 million shares in Hansa Medical through an accelerated bookbuilding to Swedish and international investors at a price of SEK 26,25 per share. Also, Hansa Medical's CEO Göran Arvidson acquired 30,000 shares in the transaction, which means that his holding now amounts to 63,000 shares.

ABG Sundal Collier AB, Carnegie Investment Bank AB and Erik Penser Bankaktiebolag acted as Joint Bookrunners in connection with the placing.

The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on December 8, 2015 at 08.30 CET.

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.

For further information, please contact:

Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com

www.hansamedical.com